Stock 4BB 4BASEBIO PLC
Add to a list
To use this feature you must be a member
Log inSign up

Ratings 4basebio PLC

Equities

4BB

GB00BMCLYF79

Market Closed - London S.E.
Other stock markets
 16:35:09 01/05/2024 BST 		5-day change 1st Jan Change
1,075 GBX +0.47% Intraday chart for 4basebio PLC +2.87% +58.09%
04-10 4basebio to supply synthetic DNA for mRNA vaccine program AN
04-10 4Basebio plc Announces the Supply of Its opDNA? DNA Products into Tier 1 Pharma Client's Vaccine Program CI

Summary

  • From a short-term investment perspective, the company presents a deteriorated fundamental situation

Strengths

  • The prospective high growth for the next fiscal years is among the main assets of the company

Weaknesses

  • The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
  • Low profitability weakens the company.
  • One of the major weak points of the company is its financial situation.
  • Based on current prices, the company has particularly high valuation levels.

Ratings chart - Surperformance

Sector: Biotechnology & Medical Research

1st Jan change Capi. Investor Rating ESG Refinitiv
4BASEBIO PLC Stock 4basebio PLC
+58.09% 172M -
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
+0.67% 42.19B
B
LONZA GROUP AG Stock Lonza Group AG
+44.30% 40.15B
A
CELLTRION, INC. Stock Celltrion, Inc.
-6.20% 28.31B
C
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+6.55% 24.63B
B-
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-21.66% 18.2B
B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+29.96% 12.01B
C+
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-1.57% 11.76B
C+
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+16.03% 10.4B
B+
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
-4.80% 9.94B
B+
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
-
EV / Sales
Price to Book
-
Price to Free Cash Flow
-
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion
-

Business Predictability

Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality
  1. Stock Market
  2. Equities
  3. 4BB Stock
  4. Ratings 4basebio PLC